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ABSTRACT 
Background: Randomized controlled trials (RCTs) are the mainstay of evaluations of 
the efficacy of psychosocial interventions. In a recent Cochrane systematic review we 
analysed the efficacy of cognitive behavioural-based psychotherapies compared to 
treatment as usual (TAU) in adults who self-harm. In this study we examine the 
content and reporting quality of TAU in these trials and their relationship to outcomes.  
Methods: Five electronic databases (CCDANCTR-Studies and References, 
CENTRAL, MEDLINE, EMBASE, and PsycINFO) were searched for RCTs, indexed 
between 1 January 1998 and 30 April, 2015, of cognitive-behavioural interventions 
compared to TAU for adults following a recent (within six months) episode of self-
harm. Comparisons were made between outcomes for trials which included different 
categories of TAU, which were grouped as: multidisciplinary treatment, 
psychotherapy only, pharmacotherapy only, treatment by primary care physician, 
minimal contact, or unclear.  
Results: 18 trials involving 2,433 participants were included. The content and 
reporting quality of TAU varied considerably between trials. The apparent 
effectiveness of cognitive behavioural psychotherapy varied according to TAU 
reporting quality and content. Specifically, effects in favour of cognitive-behavioural 
psychotherapy were strongest in trials in which TAU content was not clearly 
described (Odds Ratio: 0.29, 95% Confidence Interval 0.15 to 0.62; three trials) 
compared to those in which TAU comprised multidisciplinary treatment (Odds Ratio: 
0.79, 95% CI 0.63 to 0.97; 12 trials).  
Limitations: The included trials had high risk of bias with respect to participant and 
clinical personnel blinding, and unclear risk of bias for selective outcome reporting. 
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Conclusions: TAU content and quality represents an important source of 
heterogeneity between trials of psychotherapeutic interventions for prevention of self-
harm. Before clinical trials begin, researchers should plan to carefully describe both 
aspects of TAU to improve the overall quality of investigations. 
 
Keywords: self-harm; suicide; clinical trials; treatment as usual; methodology. 
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INTRODUCTION 
 Self-harm, defined as intentional self-injury or intentional drug overdoses 
irrespective of level of suicidal intent or type or degree of motivation  (Hawton et al., 
2003; NICE, 2011). It is a growing problem in many countries worldwide. In England 
alone, for example, there are now more than 200,000 emergency department 
presentations for self-harm each year (Hawton et al., 2007). Self-harm is also 
frequently repeated. Up to one-quarter of patients who present to hospital following 
an episode of self-harm will return to the same hospital within one year following a 
repeat episode (Carroll et al., 2014; Owens et al., 2002). Self-harm is also a 
significant risk factor for death by suicide (Carroll et al., 2014). 
Given the prevalence of self-harm, the frequency with which it is repeated, 
and its association with suicide, it is important that effective interventions are 
developed and rigorously evaluated for their effectiveness (Hawton et al., 2016a). 
Guidelines for the evaluation of complex multicomponent interventions, such as those 
typically developed for the prevention of self-harm, emphasize the primacy of the 
randomized controlled trial (RCTs) design as the randomization process can protect 
against selection bias and other threats to internal validity (Craig et al., 2008). RCTs 
of psychological interventions for self-harm typically compare the active treatment 
condition against “treatment as usual” (TAU). However, within psychiatry trials the 
TAU condition is typically poorly defined (Burns, 2009), despite calls since 1996 to 
define the components of the TAU condition as precisely as the active intervention 
condition (Burns and Priebe, 1996). 
 Complicating matters is the fact that TAU necessarily varies between studies 
as a result of service-related differences over time. It has been demonstrated, for 
example, that the apparent effectiveness of assertive community treatment (ACT) has 
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diminished over time as many of the key features of ACT, particularly with respect to 
reduced case load and increased service intensity, have come to be integrated into 
routine community care (Clarke et al., 2000). TAU will also vary between different 
locations, and especially between different countries. TAU practices can also vary 
between centres in the case of multicentre trials (Saunders and Smith, 2016), and yet, 
these differences have generally been ignored in self-harm trials. 
Variability in the TAU condition can seriously affect the magnitude of the 
effect size for the experimental intervention in RCTs of psychosocial interventions. 
For example, it has been shown that whilst manualized interventions for anxiety and 
depression (e.g., cognitive behavioural therapy [CBT]) are associated with significant 
benefits in terms of reduced symptomatology when compared to TAU, this effect is 
attenuated when limited to RCTs in which TAU contained some component of the 
active treatment (Wampold et al., 2011). Similar effects have been observed in 
psychosocial trials for cannabis cessation (Cooper et al., 2015). Effect size attenuation 
may be particularly likely in RCTs conducted in recent years as CBT has become a 
standard therapeutic approach included in the training of mental health professionals 
(Sarin et al., 2011). 
Despite these important findings the nature of TAU is rarely investigated as an 
important source of heterogeneity in meta-analyses of the effectiveness of 
psychosocial treatments (Van de Wiel et al., 2007; Watts et al., 2015). For this reason, 
we have investigated the quality of reporting for the control condition in trials of 
CBT-based therapies for self-harm to highlight the potential impact of the TAU 
condition on the magnitude of the reported treatment effect for these interventions and 
to provide guidance on reporting of TAU for future trialists in this area (Watts et al., 
2015). This work extends our recent update of the treatment literature on the 
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effectiveness of psychosocial interventions for self-harm in adults (Hawton et al., 
2016a, b), in which we conclude that there is now evidence to support the use of brief 
(i.e., up to 10 sessions) CBT-based psychotherapy for reducing the proportion of 
adults who engage in further self-harm and for having other benefits for the emotional 
well-being of patients. 
 
METHOD 
Electronic Search Strategy 
We searched for RCTs of psychosocial treatments in adults following a recent 
(within six months) episode of self-harm indexed in five electronic databases 
(CCDANCTR-Studies and References, CENTRAL, MEDLINE, EMBASE, and 
PsycINFO) between 1 January, 1998 and 29 April, 2015 using the electronic search 
strategy outlined in Supplementary Document SD1. The reference lists of 44 major 
review papers as well as ten English language specialist suicidology journals were 
also manually searched and researchers active in the field were contacted to identify 
unpublished literature inadvertently missed by the electronic search. 
 
Trial Eligibility 
RCTs were eligible for inclusion provided they met the following criteria: (1) 
used random allocation to assign participants to the intervention and control groups; 
(2) participants were 18 years or older at the point of randomization; (3) all 
participants had engaged in self-harm (defined as any non-fatal act of self-injury 
and/or intentional drug overdose irrespective of the extent of suicidal intent or any 
other type of motivation; Hawton et al., 2003) no more than six months prior to 
randomization; and (4) the trial evaluated the effectiveness of a CBT-based therapy, 
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including cognitive behavioural therapy (CBT), problem-solving therapy (PST), or a 
combination of these, relative to treatment as usual (TAU). Non-English language 
studies were eligible for inclusion in this review and were translated by native 
speakers. 
Trials were independently screened for inclusion by KW and one of TTS, EA, 
DG, PH, ET, or KvH. Disagreements were resolved following discussion with KH. 
Where insufficient information was recorded in the study report to determine 
eligibility, study authors were contacted to provide additional clarification. 
 
Data Extraction 
Outcome data 
For quantitative analyses, the primary outcome measure was repetition of self-
harm at the six month, twelve month, and final follow-up assessment points. 
Secondary outcomes included scores for depression, hopelessness, and suicidal 
ideation at the final follow-up assessment. Quantitative data relating to these 
outcomes were extracted independently by KW and one of TTS, EA, DG, PH, ET, or 
KvH. Again disagreements were resolved following discussion with KH. Study 
authors were contacted to provide additional information where data were either 
missing or unclear. 
To investigate homogeneity of the effect size estimate between studies, we 
calculated the I2 statistic, which indicates the percentage of variability in effect sizes 
between studies resulting from genuine methodological and other differences, rather 
than chance alone. This statistic can take any value between 0% and 100%, with 
values greater than 75% conventionally interpreted as indicating substantial levels of 
between-study variability (Higgins et al., 2003). 
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TAU content 
Information on the content of the TAU condition was assessed independently 
by KW and DPDM using a standard pro forma. Details extracted included definition 
of the TAU condition and whether any component/s of the active treatment condition 
was/were available to participants randomized to the TAU condition. Disagreements 
were resolved following discussion with KH. 
TAU was classified as either: (1) multidisciplinary treatment (i.e., comprising 
both psychological and pharmacological treatment from a range of psychiatric, 
personality, addictions, and/or other services according to need); (2) psychotherapy 
only; (3) pharmacotherapy only; (4) treatment by GP/primary care physician only; (5) 
minimal contact (i.e., psychoeducation, bibliotherapy, or remote contact only); or (6) 
unclear/not adequately described (Watts et al., 2015). 
 
Risk of Bias Assessment 
We also assessed risk of bias for each included trial using the approach 
favoured by the Cochrane Collaboration (Higgins et al., 2008b). Specifically, each 
study was rated as at high, unclear, or low risk of bias with respect to the following 
domains: adequacy of the random sequence generation procedure, adequacy of 
allocation concealment, and presence of participant and clinical personnel blinding, 
outcome assessor blinding, incomplete outcome data, selective outcome reporting, 
and any other bias. We also recorded information on the proportion of participants for 
whom data on the primary outcome, repetition of self-harm, was lacking at the final 
follow-up assessment. 
9 
 
For the incomplete outcome data criterion, we rated trials as high risk of bias 
where there were ≥10% missing data for the primary outcome and data had been 
analysed according to per protocol principles, and where no method had been used to 
statistically account for missing data. There was one exception to this. Where the last 
observation carried forward (LOC) method had been used to account for missing data, 
we rated these trials as unclear risk of bias for this criterion as the LOC method has 
been shown to introduce bias (Engles and Diehr, 2003). 
 
Statistical Analyses 
 Proportions of patients repeating self-harm at the six month, 12 month, and 
last available follow-up assessment were summarized using the odds ratio (OR) and 
the accompanying 95% confidence interval (CI). Data for all continuous secondary 
outcome measures, including depression, hopelessness, and suicidal ideation scores, 
were assessed using the standard mean difference (SMD) and 95% CI, as 
recommended by the Cochrane Collaboration (Higgins et al., 2008a), because the 
studies included in the meta-analysis used a variety of different psychometric 
measures to assess these outcomes. 
 Given that departure from the intention-to-treat principle, in which all 
participants are analysed in the groups to which they had been randomly allocated 
(Hollis, 1999), is associated with artificial inflation of the effect size estimate in 
treatment intervention trials (Abraha et al., 2015), where possible we analysed data 
according to the ITT principle. This approach was not always possible, however, 
particularly in cases where the outcome relied on patient self-reported data (e.g., 
depression, hopelessness, and suicidal ideation scores). In these cases we have 
therefore analysed all available case data. To account for any bias introduced by the 
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use of these data we have considered the effect of missing data for these outcomes 
within the text of the review, as recommended by the Cochrane Collaboration 
(Higgins et al., 2011). 
All analyses were undertaken in RevMan for Windows, version 5.3, using the 
Mantel-Haenszel random effects model for all dichotomous outcomes, and for 
continuous outcomes, using the inverted variance random effects model. Sub-group 
analyses to investigate whether the effectiveness of CBT-based interventions would 
vary as a result of the TAU condition were conducted using the random effects model. 
 
RESULTS 
The systematic search outlined in Supplementary Document SD1 retrieved a 
total of 23,830 citations. An additional 10 trials ongoing at the time of the systematic 
search were identified through correspondence with researchers in the field. 
Following de-duplication, the overall figure was reduced to 16,799. A total of 16,538 
were excluded following screening, whilst a further 237 were excluded after 
reviewing the full text. Seven trials were additionally excluded from the present 
review as they evaluated the effectiveness of a pharmacological intervention, whilst a 
further 11 trials were excluded as they evaluated an intervention for children and 
adolescents.  
A further 37 trials were excluded from this version of the review as they 
evaluated a psychosocial intervention other than CBT-based psychotherapy. A total of 
18 non-overlapping RCTs comparing CBT-based psychotherapy to TAU were 
therefore included in this study (Brown et al., 2005; Davidson et al., 2014; Dubois et 
al., 1999; Evans et al., 1999; Gibbons et al., 1978; Guthrie et al., 2001; Hatcher et al., 
2011; Hawton et al., 1987; Husain et al., 2014; McAuliffe et al., 2014; Patsiokas and 
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Clum, 1985; Salkovskis et al., 1990; Slee et al., 2008; Stewart et al., 2009; Tapolaa et 
al., 2010; Tyrer et al., 2003; Wei et al., 2013; Weinberg et al., 2006) (Figure 1). 
 
Study Characteristics 
 The included trials comprised a total of 2,433 participants. Of the 13 trials that 
recorded information on age, the weighted average age at randomization was 29.6 (SD 
8.3; range 15.0 to 66.0) years. Of the 16 trials that recorded information on gender, 
62.5% (n=1,833) of participants were female. All participants had engaged in at least 
one episode of SH in the six months prior to randomization. Further characteristics of 
these 18 studies can be found in Table 1. 
The majority of these 18 trials were conducted in the United Kingdom (N=7; 
(Davidson et al., 2014; Evans et al., 1999; Gibbons et al., 1978; Guthrie et al., 2001; 
Hawton et al., 1987; Salkovskis et al., 1990; Tyrer et al., 2003) followed by the United 
States of America (N=3; (Brown et al., 2005; Patsiokas and Clum, 1985; Weinberg et 
al., 2006) with one trial each from Australia (Stewart et al., 2009), China (Wei et al., 
2013), Finland (Tapolaa et al., 2010), France (Dubois et al., 1999), The Netherlands 
(Slee et al., 2008), New Zealand (Hatcher et al., 2011), Pakistan (Husain et al., 2014), 
and the Republic of Ireland (McAuliffe et al., 2014). 
 
Methodological Quality 
 The included trials had high risk of bias. All trials were rated as at high risk of 
bias with respect to participant and clinical personnel blinding and at unclear risk of 
bias for selective outcome reporting (Table 2). Additionally, trial protocols were 
generally not available as many of the trials included in this review had been 
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published before the International Committee of Medical Journal Editors’ (ICMJE) 
mandatory trial registration guidelines took effect in 2005 (De Angelis et al., 2004). 
Four further trials (22.2%) were rated as at high risk of bias for outcome 
assessor blinding. In two cases this was because all outcomes relied on self-reported 
measures and participants themselves were not blind to treatment allocation (Guthrie 
et al., 2001; Slee et al., 2008), whilst in the remaining two cases, outcome assessor 
blinding could not be achieved due to feasibility limitations (Brown et al., 2005; 
Stewart et al., 2009). Performance and detection bias therefore cannot be ruled out for 
the majority of the trials included in this review. 
 One study (5.6%) was rated as at high risk of bias for allocation concealment 
as this study made use of Zelen’s post-randomization consent procedure in which 
participants are asked to consent to inclusion in the trial after being notified to which 
group, intervention or TAU, they were allocated (Hatcher et al., 2011). Selection bias 
therefore cannot be ruled out. 
 In nine trials there were either no withdrawals from the study (Davidson et al., 
2014; Gibbons et al., 1978; Guthrie et al., 2001; Hawton et al., 1987; Salkovskis et al., 
1990; Weinberg et al., 2006), or, less than 10% of the participant pool could not be 
located at follow-up (Evans et al., 1999; Husain et al., 2014; Slee et al., 2008). In two 
trials (11.1%) either no information was provided on the amount of missing data at 
follow-up (Patsiokas and Clum, 1985), or, no apparent attempt was made to follow-up 
patients post-intervention (Stewart et al., 2009). In three further trials, although 
greater than 10% of the participant pool could not be located at the final follow-up 
assessment, nonetheless, appropriate measures were used to account for missing data 
(Brown et al., 2005; Hatcher et al., 2011; Wei et al., 2013). For the remaining four 
trials (38.9%), greater than 10% of the allocated participants could not be located at 
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the final follow-up assessment and no apparent attempt was made to statistically 
account for missing data (Dubois et al., 1999; McAuliffe et al., 2014; Tapolaa et al., 
2010; Tyrer et al., 2003). Missing data were a greater concern for the TAU arm as 
compared to the intervention arm (weighted average 12.4% versus 8.4%). 
 
Description of Treatment As Usual 
The content of TAU for each of the studies is summarized in Table 3. In most 
studies a description of the TAU control condition was provided a priori (83.3%). For 
the majority of these trials TAU was multidisciplinary in nature, combining 
psychotherapy, pharmacotherapy, and referral to specialist services (e.g., personality 
disorder, addictions, and other services) as required (Davidson et al., 2014; Dubois et 
al., 1999; Evans et al., 1999; Gibbons et al., 1978; Guthrie et al., 2001; Hatcher et al., 
2011; McAuliffe et al., 2014; Patsiokas and Clum, 1985; Slee et al., 2008; Stewart et 
al., 2009; Tapolaa et al., 2010; Tyrer et al., 2003; Weinberg et al., 2006). For two 
further trials TAU comprised referral to the participant’s primary care physician 
(Hawton et al., 1987; Husain et al., 2014).  
In two trials (11.1%), however, there was no description of the TAU condition 
(Salkovskis et al., 1990; Wei et al., 2013). In one further trial (5.6%) insufficient 
details of TAU content were provided (Brown et al., 2005). In line with previous work 
(Watts et al., 2015), we therefore categorized the TAU condition in these three trials 
as unclear. 
 
Effect of Treatment As Usual Condition on Repetition of Self-Harm 
As we have previously reported (Hawton et al., 2016a, b), CBT-based 
psychotherapy was associated with a significant reduction in the proportion of people 
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repeating self-harm at the final follow-up assessment in these trials (OR 0.70, 95% CI 
0.55 to 0.88; p=0.003; Figure 2). However, sub-group analyses demonstrated that the 
TAU condition was significantly associated with variability in the finding regarding 
the effectiveness of CBT-based psychotherapy (χ2=6.38, df=2, p=0.04, I2=68.6%; 
Figure 2). Specifically, whilst CBT-based psychotherapy was strongly associated with 
a significant treatment effect for repetition of self-harm when compared to an unclear 
TAU condition (OR 0.29, 95% CI 0.13 to 0.62; 3 trials), the effect size was reduced 
when compared to multidisciplinary TAU (OR 0.79, 95% CI 0.63 to 0.97; 12 trials). 
CBT-based psychotherapy was not associated with a treatment effect for repetition of 
self-harm at this assessment point when compared to GP management (OR 053, 95% 
CI 0.15 to 1.93; two trials; Figure 2). However, it is important to note that only two 
trials were included in this latter sub-group and therefore the estimate of effect for this 
finding is imprecise. 
 
Effect of Treatment As Usual Condition on Suicidal Ideation Scores 
 CBT-based psychotherapy was associated with a significant treatment effect 
for suicidal ideation scores at the final assessment point (SMD -0.28, 95% CI -0.47 to 
-0.09; p=0.003; Figure 3). There was no evidence of a significant difference in the 
effect size as a result of the TAU comparator condition used (χ2=0.05, df=1, p=0.83; 
I2=0%; Figure 3).  
 
Effect of Treatment As Usual Condition on Depression Scores 
 CBT-based psychotherapy was associated with a significant treatment effect 
for depression scores at the final follow-up assessment (SMD -0.31, 95% CI -0.48 to -
0.14; p=0.0003; Figure 4). Although the effect for CBT-based psychotherapy on 
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depression scores was strongest when compared against multidisciplinary TAU (SMD 
-0.35, 95% CI -0.58 to -0.12; 9 trials), followed by GP management (SMD -0.28, 95% 
CI -0.52 to -0.04; 2 trials), and non-significantly associated with a treatment effect for 
depression scores when compared to unclear TAU (SMD -0.33, 95% CI -0.94 to 0.28; 
3 trials), these sub-group differences were not significant (χ2=0.18, df=2, p=0.91, 
I2=0%; Figure 4).  
 
Effect of Treatment As Usual Condition on Hopelessness Scores 
 CBT-based psychotherapy was associated with a significant reduction in 
hopelessness scores at the final follow-up assessment (SMD -0.31, 95% CI -0.51 to -
0.10; p=0.003; Figure 5). Although this effect appeared to be strongest when CBT-
based psychotherapy was compared to an unclear TAU condition (SMD -0.68, 95% 
CI -1.80 to 0.43; 2 trials), in contrast to where TAU comprised either GP management 
(SMD -0.41, 95% CI -0.68 to -0.14; 1 trial)  or multidisciplinary TAU (SMD -0.22, 
95% CI -0.45 to 0.01; 4 trials), these subgroup differences were not significant 
(χ2=1.61, df=2, p=0.45, I2=0%; Figure 5).  
 
 
DISCUSSION 
 We have previously shown that CBT-based psychotherapy is associated with 
significant post-treatment reductions in self-harm, depression, hopelessness, and 
suicidal ideation, but not suicide (although the number of events for this outcome was 
relatively small) (Hawton et al., 2016a, b). However, differences in the quality of the 
TAU comparator condition between trials still represents an important source of 
variability (Arensman et al., 2001). The aim of the present review, therefore, was to 
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highlight the potential impact of the TAU condition on estimates of treatment effects 
for these interventions and to provide reporting guidance for future trials in this area. 
 In few trials were details provided of the treatment components offered to 
participants allocated to the TAU condition. In fewer still was the number of treatment 
sessions attended by control participants reported. Additionally, and particularly 
importantly, no author provided a detailed break-down of the treatments actually 
received by participants in the TAU condition. This is in contrast to a recent report on 
an RCT of dialectical behaviour therapy for self-harm in adults which includes a 
supplementary table outlining the various treatments received by participants 
allocated to the TAU condition and the mean number of months the participants 
received each of these components (Priebe et al., 2012). We recommend that in future 
trials of psychosocial interventions for self-harm in which TAU is the control 
condition researchers should, where possible, aim to reproduce such tables to assist in 
calculating treatment dosage for participants allocated to the TAU arm. 
  
Recommendations for TAU Treatment Conditions 
 Although in most trials included in this review some description of the content 
of the TAU condition was provided (83.3%), sub-group analyses suggested evidence 
of a significant difference in effectiveness for CBT-based psychotherapy for the 
primary outcome measure, repetition of self-harm, for those studies in which TAU 
content was not adequately described. However, it should be noted that, generally, for 
those trials in which TAU content was not clearly described they were also rated as 
being or poor quality in other aspects of trial design. Thus, we cannot we clear if this 
finding is specific to description of TAU content, or a more global consequence of 
trial design. Also, given that components of CBT-based psychotherapy may have 
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come to be integrated into TAU across a number of services internationally, this 
finding may also be partly explained by potential similarities between the CBT-based 
psychotherapy treatment condition and the TAU condition. However, this cannot be 
verified at the present time due to limited information on TAU content in many of the 
included studies.  
 For the secondary outcome measure of depression scores, in contrast, we 
found a non-significant trend towards stronger effects for CBT-based psychotherapy 
when compared to multidisciplinary TAU as compared to when TAU content was not 
adequately described. However, the effect for hopelessness scores was consistent with 
that observed for repetition of self-harm. As no studies that reported outcome data for 
suicidal ideation scores were rated as unclear TAU, we were unable to investigate the 
impact of an unclear TAU condition on the magnitude of the effect size for this 
outcome. 
 In none of the included trials were there clear descriptions of the treatment 
components (e.g., psychotherapy, pharmacotherapy, welfare) available to participants 
assigned to the TAU condition and the number of participants that received each of 
these. We suggest that in future trials researchers should where possible provide 
details on the type(s) of treatments available to participants assigned to the TAU 
group, the number of patients in the TAU condition who received each component(s) 
and the number of patients involved in follow-up assessments. The number and 
frequency of contacts with each component(s) should also be specified where 
possible. We acknowledge, however, that it may not always be possible to record 
details on the treatment received by participants assigned to the TAU group to the 
same level of detail as for those assigned to the intervention group due to budgetary 
and other considerations. Further detail on the component(s) of TAU actually 
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received, however, will help to determine whether the TAU condition reflects current 
clinical best-practice for the treatment setting, and whether the TAU condition 
controlled for any non-specific effect(s) of the intervention condition. 
For one trial in which the intervention treatment was offered in a group-based 
format, TAU involved referral for predominately individual-based psychotherapy 
(McAuliffe et al., 2014). Offering psychotherapy in a group-based environment may 
provide a number of additional beneficial effects beyond the hypothesized mechanism 
of change for this intervention, such as helping participants overcome social isolation. 
Alternatively, offering treatment in a group-based format may be detrimental for this 
patient group, given findings from one Australian trial of group-based CBT with 
adolescent self-harm patients in which information shared during a group-based 
psychotherapy session was posted on a participant’s personal web-blog (Hazell et al., 
2009). There may also be more detrimental effects of group-based CBT when self-
harm patients with a history of frequent self-harm repetition are involved, as they may 
be particularly vulnerable to the social contagion effects of self-harm (Haw et al., 
2013). 
 
Strengths and Limitations 
The primary strength of this review relates to the systematic approach used to 
identify and include data from all relevant trials and the extent to which most of them 
include detailed information on content of therapy and outcomes. In all trials there 
were far more details of the experimental treatment compared to TAU. The included 
trials all had risk of bias in that they were rated as at high risk of bias with respect to 
participant and clinical personnel blinding and at unclear risk of bias for selective 
outcome reporting. In part, however, this reflects the fact that the trials included in 
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this review examined the effectiveness of psychotherapy and it is generally not 
possible to blind either the participants themselves, or the therapists delivering 
treatment, to psychological therapy. There was also considerable variability in the 
proportion of participants for whom follow-up information on the primary outcome 
measure, repetition of self-harm, was lacking, ranging from 0% for six studies to over 
half (63.2%) for one study. In the main this likely reflects differences in the approach 
used to ascertain repetition. For those studies in which repetition of self-harm was 
ascertained from medical and/or hospital records, rates of missing data were lower 
than in those in which self-reported information was used as these data would only 
have been available for those able to be located at follow-up and may additionally 
have been affected by recall and other biases. 
 
Conclusions 
 The present review suggests that whilst, overall, CBT-based psychotherapy 
was more effective than TAU in reducing the proportion of participants who self-harm 
and also depression, hopelessness and suicidal ideation at final follow-up, results 
varied by TAU content. Specifically, effects in favour of CBT-based psychotherapy in 
reducing repetition of self-harm were strongest where the TAU was not clearly 
described. The study shows that TAU content and quality is a significant, but 
infrequently investigated, source of heterogeneity between trials of interventions for 
the prevention of self-harm and, furthermore, that TAU is not a homogenous 
comparator. We suggest that in future, researchers in this field should carefully 
describe both the nature of TAU and what participants in this condition actually 
received in order to improve the overall quality of trials of psychological interventions 
and the interpretation of the findings for application in treatment services.
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Table 1. Methodological details of the 18 trials of CBT included in this review. 
Study Country 
N 
Age 
(SD) 
Female 
(%) 
History of 
self-harm 
(%) 
Participant 
Source 
Treatment 
Duration 
N (%) Lacking 
Follow-Up  
Information1 
Measures Risk of Bias 
INV CTL 
Brown et al., 2005 USA 60 
 
60 
 
 
35.0 
(10.3) 
60.8 72.5 Patients presenting 
to hospital following 
a suicide attempt. 
Between 10-20 
weeks. 
35/120  
(20.8%) 
Self-harm: self-reported. 
Depression: Beck Depression Inven-
tory (BDI) and Hamilton Rating 
Scale for Depression (HAM-D). 
Hopelessness: Beck Hopelessness 
Scale (BHS) 
Suicidal ideation: Beck Scale for Sui-
cidal Ideation (BSSI), dichotomised. 
Suicide: NR. 
Participants, clinical personnel, and 
outcome assessors not blind to allo-
cation.  
Davidson et al., 2014 UK 14 6 NR NR NR Patients admitted to 
the medical ward of 
local accident and 
emergency depart-
ments following an 
episode of self-harm. 
NR. 0/772  
(0.0%) 
Self-harm: self-reported according to 
the Acts of Deliberate Self-Harm In-
ventory. 
Depression: Hospital Anxiety and 
Depression Rating Scale (HADRS). 
Suicidal Ideation: BSSI. 
Suicide: NR. 
Nature of trial suggests participants 
and clinical personnel not blind to al-
location. Imbalance between inter-
vention and control groups in terms 
of history of previous self-harm, anx-
iety, and depression scores. Authors 
did not adjust for these differences in 
their analyses. 
Dubois et al., 1999 France 51 51 22.3  
(5.8) 
80.4 NR Patients attending 
any emergency de-
partment following 
self-harm. 
1 month. 18/102  
(17.6%) 
Self-harm: NR. 
Suicide: NR. 
Nature of trial suggests participants 
and clinical personnel not blind to al-
location. Unclear if outcome assessor 
also bind to allocation. Less than 
two-thirds of participants in the inter-
vention group attended all three treat-
ment sessions. 
Evans et al., 1999 UK 18 16 NR 61.8 100.0 Patients admitted to 
general hospitals fol-
lowing an episode of 
self-harm. 
6 months. 2/34  
(5.9%) 
Self-harm: self-report according to 
the Linehan Parasuicide History In-
terview, supplemented by hospital 
records. 
Depression: HADRS. 
 
Nature of trial suggests participants 
and clinical personnel not blind to al-
location. Five participants in the in-
tervention group did not see a thera-
pist and instead received bibliother-
apy whilst one further participant re-
ceived no intervention. 
Gibbons et al., 1978 UK 200 200 NR 71.0 NR Patients presenting 
to accident and 
emergency depart-
ments following an 
episode of self-poi-
soning. 
3 months. 0/400  
(0.0%) 
Self-harm: hospital and/or medical 
records. 
Depression: BDI. 
Problem-solving: self-report. 
 
Nature of trial suggests participants 
and clinical personnel not blind to al-
location. 
Guthrie et al., 2001 UK 58 61 31.2 
(1.5) 
54.6 59.7 Patients presenting 
to hospital following 
an episode of self-
poisoning. 
4 weeks. 0/119  
(0.0%) 
Self-harm: self-report supplemented 
by medical records. 
Depression: BDI scores. 
Suicidal ideation: BSSI. 
Suicide: NR. 
Nature of trial suggests participants 
and clinical personnel not blind to al-
location. Although outcome asses-
sors blind to allocation, data on repe-
tition of SH obtained from self-re-
port. 
Hatcher et al., 2011 NZ 253 299 33.7 
(12.9) 
68.8 44.7 Patients admitted to 
hospital following an 
episode of self-harm. 
3 months. 158/1094 
(14.4%) 
Self-harm: hospital records. 
Depression: HADRS. 
Hopelessness: BHS. 
Nature of trial suggests participants not 
blind to allocation. Clinical personnel not 
blind to allocation. 
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Suicidal ideation: BSSI. 
Problem-solving: Social Problem 
Solving Inventory, Revised (SPS-R). 
Suicide: Coroners’ records. 
 
Hawton et al., 1987 UK 41 39 29.3 
(NR) 
66.3 31.2 Patients admitted to 
a general hospital 
following an episode 
of self-poisoning. 
NR. 0/80  
(0.0%) 
Self-harm: self-report, supplemented 
by hospital and medical records. 
Depression: BDI. 
Problem-solving: self-report. 
Suicide: collateral informant report. 
Nature of trial suggests participants and 
clinical personnel not blind to allocation. 
Husain et al., 2010 Pakistan 108 113 23.1 
(5.5) 
68.8 4.1 Patients admitted to 
the medical unit of a 
university hospital 
following an episode 
of self-harm. 
3 months. 8/221  
(3.6%) 
Self-harm: self-report according to 
the Suicide Attempt Self-Injury Inter-
view. 
Depression: BDI. 
Hopelessness: BHS. 
Suicidal ideation: BSSI. 
Problem-solving: Coping Resource 
Inventory (CRI). 
Suicide: NR. 
Participants and clinical personnel not blind 
to allocation. 
McAuliffe et al., 
2014 
Republic of 
Ireland 
222 211 33.5  
(11.8) 
29.8 29.3 Admissions to emer-
gency departments 
or an acute psychiat-
ric unit following an 
episode of self-harm. 
6 weeks. 107/433  
(24.7%) 
Self-harm: self-report (at 6 weeks 
post-intervention and 6 months’ fol-
low-up) and hospital records (at 12 
months’ follow-up). 
Depression: BDI. 
Hopelessness: BHS. 
Suicidal ideation: BSSI. 
Problem-solving: Self-Rated Problem 
Solving Scale (SRPSS). 
Suicide: NR. 
Participants and clinical personnel not blind 
to allocation. 
Patsiokas & Clum, 
1985 
USA 10 5 NR NR NR Admissions to a psy-
chiatric ward follow-
ing an episode of 
self-harm. 
3 weeks. N/A2 Self-harm: NR. 
Hopelessness: BHS. 
Suicidal ideation: BSSI and Self-
Monitoring of Suicidal Ideation. 
Problem-solving: Means-Ends Prob-
lem-Solving (MEPS). 
Nature of trial suggests participants and 
outcome assessors not blind to allocation. 
As same therapist delivered intervention 
and control therapies, clinical personnel 
also not blind to allocation. 
Salkovskis et al., 
1990 
UK 12 8 27.2 
(6.7) 
50.0 100.0 Referrals from the 
duty psychiatrist fol-
lowing an episode of 
self-poisoning in-
volving antidepres-
sants that necessi-
tated admission to an 
accident and emer-
gency department. 
1 month. 0/20 
(0.0%) 
Self-harm: hospital records. 
Depression: BDI. 
Hopelessness: BHS. 
Suicidal ideation: BSSI. 
Problem-solving: Personal Question-
naire Rapid Scaling Technique. 
Suicide: NR. 
Nature of trial suggests participants, clini-
cal personnel, and outcome assessors not 
blind to allocation. 
Slee et al., 2008 The Neth-
erlands 
40 42 24.7 
(5.5) 
93.9 NR. Admissions to emer-
gency departments 
or mental health cen-
tres. 
5.5 months. 8/90 
(8.9%) 
Self-harm: self-report. 
Depression: BDI. 
Suicidal ideation: Suicide Cognition 
Scale. 
Problem-solving: Coping Inventory 
for Stressful Situations. 
Suicide: NR. 
Participants, clinical personnel, and out-
come assessors not blind to allocation. Of 
the 90 participants randomized, eight did 
not receive the intervention. Reasons for 
this were not stated. 
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Table Notes: NR: not reported; NZ: New Zealand; UK: United Kingdom; USA: United States of America. 
1 Proportion (%) missing data for the primary outcome, repetition of self-harm at the final follow-up assessment. 
2 Proportion (%) missing data not reported for this trial cannot be ascertained as data for repetition of self-harm was not reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stewart et al., 2009 Australia 23 9 NR 53.1 NR Admissions to hospi-
tal following an epi-
sode of self-harm. 
2 months. NR Self-harm: hospital records. 
Hopelessness: BHS. 
Suicidal ideation: BSSI. 
Problem-solving: SPS-R. 
Suicide: NR. 
Participants, clinical personnel, and out-
come assessors not blind to allocation. Data 
only collected on treatment completers. 
Tapolaa et al., 2010 Finland 9 7 33.2  
(NR) 
100.0 NR Admissions to emer-
gency departments 
following an episode 
of self-harm. 
4 weeks. 3/16 
(18.7%) 
Self-harm: self-report according to 
the SASII. 
Depression: BDI. 
Suicide: NR. 
Nature of trial suggests participants and 
outcome assessors not blind to allocation. 
Outcome assessor not blind to allocation.  
Data only collected on treatment complet-
ers. 
Tyrer et al., 2003 UK 239 241 32.0 
(11.0) 
67.9 NR Admissions to hospi-
tal following an epi-
sode of self-harm. 
Between 3 and 
6 months. 
50/480 
(10.4%) 
Self-harm: self-report supplemented 
by medical records. 
Depression: HADRS. 
Suicide: Coroners’ records. 
Nature of trial suggests participants, clini-
cal personnel, and outcome assessors not 
blind to allocation. 
Wei et al., 2013 China 82 77 31.8 
(12.9) 
73.5 NR Admissions to emer-
gency departments 
following an episode 
of self-harm. 
3 months. 151/239 
(63.2%) 
Self-harm: self-report. 
Depression: HAM-D. 
Suicidal ideation: BSSI. 
Suicide: collateral informant report. 
Nature of trial suggests participants, clini-
cal personnel, and outcome assessors not 
blind to allocation. 
Weinberg et al., 2006 USA 15 15 28.2 
(8.2) 
100.0 NR Community referrals 
following an episode 
of self-harm. 
2 months. 0/30 
(0.0%) 
Self-harm: self-report according to 
the SASII. 
Depression: HAM-D. 
Suicidal ideation: Suicide Behaviors 
Questionnaire, suicidal ideation sub-
scale. 
Suicide: NR. 
Nature of trial suggests participants, clini-
cal personnel, and outcome assessors not 
blind to allocation. 
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Table 2: Summary of Risk of bias for the included studies according to the Cochrane Risk of Bias Tool. 
 
Study 
Risk of Bias Domains 
Random Sequence 
Generation 
Allocation 
Concealment 
Participant 
Blinding 
Clinical Personnel 
Blinding 
Outcome Assessor 
Blinding 
Incomplete Outcome 
Data 
Selecting Reporting 
Brown et al., 2005 Low Unclear High High High Low Unclear 
Davidson et al., 2014 Low Unclear High High Low Low Unclear 
Dubois et al., 1999 Unclear Unclear High High Unclear High Unclear 
Evans et al., 1999 Unclear Low High High Low Low Unclear 
Gibbons et al., 1978 Low Low High High Low Low Unclear 
Guthrie et al., 2001 Low Low High High High Low Unclear 
Hatcher et al., 2011 Low High High High Low Low Unclear 
Hawton et al., 1987 Low Low High High Low Low Unclear 
Husain et al., 2010 Low Low High High Low Low Unclear 
McAuliffe et al., 2014 Low Low High High Low High Unclear 
Patsiokas & Clum, 1985 Unclear Unclear High High Unclear Unclear Unclear 
Salkovskis et al., 1990 Low Low High High Unclear Low Unclear 
Slee et al., 2008 Low Low High High High Low Unclear 
Stewart et al., 2009 Low Unclear High High High Unclear Unclear 
Tapolaa et al., 2010 Low Unclear High High Unclear High Unclear 
Tyrer et al., 2003 Low Low High High Unclear High Unclear 
Wei et al., 2013 Low Unclear High High Unclear Low Unclear 
Weinberg et al., 2006 Low Low High High Low Low Unclear 
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Table 3. Treatment as usual (TAU) definition and classification for the 18 studies included in this review. 
Study TAU Content and Quality Description 
TAU 
Classification 
Brown et al., 2005 “Participants in both study groups received usual care from clinicians in the community as well as tracking and referral services…” (p.565). Unclear/Not Described 
Davidson et al., 2014 “Treatment as usual (TAU) was referral to a community mental health team and included appointments from a psychiatrist and community psychiatric nurse. In-patient treatment was 
given when required” (p.109). 
Multiple Providers 
Dubois et al., 1999 “[Le] cohort ‘témoin’ bénéficie d’une prise en charge classique…d’un entretien cliniquepsychiartique et à la sortie de l’hôpital d’une orientation aspécidique vers un suivi psychiatrique 
or psychologique” (p.558). [The usual care cohort received traditional care…an assessment by a clinical psychiatrist and, on leaving the hospital, were followed-up by a psychiatrist or 
psychologist]. 
Multiple Providers 
Evans et al., 1999 “Patients allocated to TAU received the standard psychiatric treatment for their condition with no restrictions apart from the use of the experimental treatment. This included in-patient 
psychiatric treatment, out-patient care, day hospital care and community treatment” (p.21). 
Multiple Providers 
Gibbons et al., 1978 “[Control] patients received the routine service: referral back to a G.P. (54 per cent); psychiatric referral (33 per cent); and other referral (13 per cent)” (p.113). Multiple Providers 
Guthrie et al., 2001 “Patients who were randomised to the ‘treatment as usual’ arm received routine care. In most cases this consists of an assessment by a casualty doctor or junior psychiatrist in the 
emergency department, on the basis of which about one third patients are referred for follow up as a psychiatry outpatient, a small number are referred to addiction services, and the 
remainder are advised to consult their own general practitioner. No patients are routinely referred to psychotherapy of psychology services” (p.2). 
Multiple Providers 
Hatcher et al., 2011 “Usual care following self-harm varies and may involve referral to multidisciplinary teams for psychiatric or psychological intervention, referral to mental health crisis teams, 
recommendations for engagement with alcohol and drug treatment centres or other health and non-health services.” (p.311). 
Multiple Providers 
Hawton et al., 1987 “[Treatment as usual involved d]ischarge summaries sent by the counsellors to the general practitioners [and] included recommendations for them to provide or arrange further care (e.g., 
marital therapy, individual support)…patients in either treatment group were [also] offered telephone ‘open access’ to the general hospital psychiatric service…” (p.752). 
GP Management. 
Husain et al., 2010 “Local medical, psychiatric and primary care services provided standard routine care. Participants received an initial assessment along with TAU as ascertained by their treating doctor or 
their primary care physician (general practitioner, GP). Patients are not routinely referred to psychiatric or psychology services.” (p.464). 
GP Management 
McAuliffe et al., 2014 “Treatment as usual involved assessment by mental health professional staff and by crisis nurses. Psychosocial assessment of all [TAU] patients was carried out by a psychiatrist (liaison 
psychiatry or mental health team) to determine mental health needs and level of risk to self or others. Patients who had no contact with mental health services during the previous year 
and not requiring referral on to mental health acute or community-based services were referred to the crisis nurse service for further psychosocial assessment and suicide risk 
assessment…Those who were referred on by the psychiatrist to mental health acute or community-based services were commonly offered pharmacological treatment and review by the 
mental health team and less frequently counselling or psychotherapy” (p.385). 
Multiple Providers 
Patsiokas & Clum, 1985 “Nondirective control…The subjects in this group had individual sessions in which an open discussion occurred on their suicidal behaviour, problems, and daily lives” (p.283). Psychotherapy Only 
Salkovskis et al., 1990 “ ‘Treatment as usual’ was used as the comparison group…” (p.872). Unclear/Not Described 
Slee et al., 2008 “We recorded three forms of TAU: psychotropic medication, psychotherapy and psychiatric hospitalisations.” (p.205). 
 
Multiple Providers 
Stewart et al., 2009 “Community follow-up was offered by the respective HSDs Acute Care Team (ACT) and formed the treatment as usual (TAU) condition for the purpose of the current study. Follow-up 
consisted of telephone calls, home visits, appointments with the psychiatrist, liaison with the client’s general practitioner, or networking with social supports” (p.539). 
Multiple Providers 
Tapolaa et al., 2010 “We recorded three forms of TAU: psychotropic medication, psychiatric hospitalization, and outpatient sessions with a mental health worker (not a qualified psychotherapist)” (p.99). Multiple Providers 
Tyrer et al., 2003 “Patients allocated to TAU were seen by another designated therapist and offered the standard treatment in the area concerned or the continuation of this 
if already implemented; this varied from problem solving approaches…dynamic 
psychotherapy…GP or voluntary group referral…or short-term counselling” (p.970). 
Psychotherapy Only 
Wei et al., 2013 “Patients in the control group did not receive any interventions” (p.109). Unclear/Not Described 
Weinberg et al., 2006 “TAU included 5 patients treated by a psychiatrist, 3 by a community mental health worker, 4 by a social worker, and 2 who received no treatment. No information was reported on 
treatment for the remaining two TAU participants” (p.483). 
Multiple Providers 
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Figure 1. PRISMA flow diagram of included and excluded studies for this version of 
the review. 
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Additional records identified 
through other sources  
(n = 10) 
Records after duplicates removed 
(n = 16,799) 
Records screened 
(n = 16,799) 
Records excluded 
(n = 16,538) 
Full-text articles 
assessed for eligibility 
(n = 310) 
Full-text articles excluded, with reasons 
(n = 292) 
 
Not all participants self-harmed (n = 98) 
Non-randomised design (n = 66) 
Not CBT-based psychotherapy (n = 37) 
Reviews, editorials, conferences (n = 28) 
Trial protocols (n = 24) 
Self-harm not within 6 months of inclusion (n= 11) 
Investigated intervention for children (n = 11) 
Investigated pharmacological intervention (n = 7) 
Secondary publications already included (n = 4) 
Not intervention for prevention of SH (n = 4) 
Data from only one trial arm presented (n= 1) 
Follow-up period greater than 2 years (n = 1) 
Studies included in 
review 
(n = 18) 
Non-overlapping trials 
included in previous 
updates (n = 49) 
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Figure 2. Random effects odds ratio (OR) and 95% confidence interval (CI) for 
repetition of self-harm at the final follow-up assessment sub-grouped according to 
TAU condition. 
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Figure 3. Random effects standard mean difference (SMD) and 95% confidence 
interval (CI) for suicidal ideation scores at final follow-up sub-grouped according to 
TAU condition. 
 
  
30 
 
 
Figure 4. Random effects standard mean difference (SMD) and 95% confidence 
interval (CI) for depression scores at final follow-up sub-grouped according to TAU 
condition. 
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Figure 5. Random effects standard mean difference (SMD) and 95% confidence 
interval (CI) for hopelessness scores at final follow-up sub-grouped according to TAU 
condition. 
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